Grace M. Aldrovandi

Grace M. Aldrovandi

Auto-generated profile, based on publicly available information

Grace M. Aldrovandi

Division of Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at the University of California, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
PPPia S. Pannaraj
Pia S. Pannaraj
FLFan Li
Fan Li
CCChiara Cerini
Chiara Cerini
JBJeffrey M. Bender
Jeffrey M. Bender
SYShangxin Yang
Shangxin Yang
GAGrace M. Aldrovandi
Grace M. Aldrovandi
Microbial colonization of the infant gut plays an important role in lifelong health.1,2 In healthy newborns, the gut microbiome composition shows large-scale longitudinal changes until age 3 years, when it settles into an adult-like anaerobic pattern.3-5 Perturbations in the microbiome are associated with susceptibility to autoimmune diseases, such as diabetes, inflammatory bowel disease, atopy, and other conditions.6-8 The mechanisms of acquisition and progression toward a “normal” infant microbiome are poorly understood. Colonization of the infant gut is a complex process dependent on multiple overlapping factors, including age,9 mode of delivery,10-12 type of feeding,10,12,13 and environmental exposures.14

10 July 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
LKLouise Kuhn
Louise Kuhn
GAGrace M. Aldrovandi
Grace M. Aldrovandi
MSMoses Sinkala
Moses Sinkala
CKChipepo Kankasa
Chipepo Kankasa
KSKatherine Semrau
Katherine Semrau
DTDonald M. Thea
Donald M. Thea
In low-resource settings, many programs recommend that women who are infected with the human immunodeficiency virus (HIV) stop breast-feeding early. We conducted a randomized trial to evaluate whether abrupt weaning at 4 months as compared with the standard practice has a net benefit for HIV-free survival of children. We enrolled 958 HIV-infected women and their infants in Lusaka, Zambia. All the women planned to breast-feed exclusively to 4 months; 481 were randomly assigned to a counseling program that encouraged abrupt weaning at 4 months, and 477 to a program that encouraged continued breast-feeding for as long as the women chose. The primary outcome was either HIV infection or death of the child by 24 months. In the intervention group, 69.0% of the mothers stopped breast-feeding at 5 months or earlier; 68.8% of these women reported the completion of weaning in less than 2 days. In the control group, the median duration of breast-feeding was 16 months. In the overall cohort, there was no significant difference between the groups in the rate of HIV-free survival among the children; 68.4% and 64.0% survived to 24 months without HIV infection in the intervention and control groups, respectively (P=0.13). Among infants who were still being breast-fed and were not infected with HIV at 4 months, there was no significant difference between the groups in HIV-free survival at 24 months (83.9% and 80.7% in the intervention and control groups, respectively; P=0.27). Children who were infected with HIV by 4 months had a higher mortality by 24 months if they had been assigned to the intervention group than if they had been assigned to the control group (73.6% vs. 54.8%, P=0.007). Early, abrupt cessation of breast-feeding by HIV-infected women in a low-resource setting, such as Lusaka, Zambia, does not improve the rate of HIV-free survival among children born to HIV-infected mothers and is harmful to HIV-infected infants.(ClinicalTrials.gov number, NCT00310726.)

1 June 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
AGAdva Gadoth
Adva Gadoth
MHMegan Halbrook
Megan Halbrook
RMRachel Martin-Blais
Rachel Martin-Blais
AGAshley Gray
Ashley Gray
NTNicole H. Tobin
Nicole H. Tobin
ARAnne W Rimoin
Anne W Rimoin

28 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KKKattayoun Kordy
Kattayoun Kordy
TGThaidra Gaufin
Thaidra Gaufin
MMMartin Mwangi
Martin Mwangi
FLFan Li
Fan Li
CCChiara Cerini
Chiara Cerini
GAGrace M. Aldrovandi
Grace M. Aldrovandi
Increasing evidence supports the importance of the breast milk microbiome in seeding the infant gut. However, the origin of bacteria in milk and the process of milk microbe-mediated seeding of infant intestine need further elucidation. Presumed sources of bacteria in milk include locations of mother-infant and mother-environment interactions. We investigate the role of mother-infant interaction on breast milk microbes. Shotgun metagenomics and 16S rRNA gene sequencing identified milk microbes of mother-infant pairs in breastfed infants and in infants that have never latched. Although breast milk has low overall biomass, milk microbes play an important role in seeding the infant gut. Breast milk bacteria were largely comprised of Staphylococcus, Streptococcus, Acinetobacter, and Enterobacter primarily derived from maternal areolar skin and infant oral sites in breastfeeding pairs. This suggests that the process of breastfeeding is a potentially important mechanism for propagation of breast milk microbes through retrograde flux via infant oral and areolar skin contact. In one infant delivered via Caesarian section, a distinct strain of Bifidobacteria breve was identified in maternal rectum, breast milk and the infant’s stool potentially suggesting direct transmission. This may support the existence of microbial translocation of this anaerobic bacteria via the enteromammary pathway in humans, where maternal bacteria translocate across the maternal gut and are transferred to the mammary glands. Modulating sources of human milk microbiome seeding potentially imply opportunities to ultimately influence the development of the infant microbiome and health.

27 July 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JBJeffrey M. Bender
Jeffrey M. Bender
FLFan Li
Fan Li
SMShoria Martelly
Shoria Martelly
EBErin Byrt
Erin Byrt
VRVanessa Rouzier
Vanessa Rouzier
GAGrace M. Aldrovandi
Grace M. Aldrovandi
Maternal HIV infection may affect the infant’s microbiome, and this may contribute to the increased morbidity and mortality of HIV-exposed, uninfected infants.

8 January 2020 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
DJDvora Leah Joseph-Davey
Dvora Leah Joseph-Davey
JPJillian Pintye
Jillian Pintye
JBJared M Baeten
Jared M Baeten
GAGrace Aldrovandi
Grace Aldrovandi
RBRachel Baggaley
Rachel Baggaley
FGfor the PrEP in Pregnancy Working Group
for the PrEP in Pregnancy Working Group
Introduction: HIV incidence is high during pregnancy and breastfeeding with HIV acquisition risk more than doubling during pregnancy and the postpartum period compared to when women are not pregnant. The World Health Organization recommends offering pre‐exposure prophylaxis (PrEP) to pregnant and postpartum women at substantial risk of HIV infection. However, maternal PrEP national guidelines differ and most countries with high maternal HIV incidence are not offering PrEP. We conducted a systematic review of recent research on PrEP safety in pregnancy to inform national policy and rollout.Methods: We used a standard Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) approach to conduct a systematic review by searching for completed, ongoing, or planned PrEP in pregnancy projects or studies from clinicaltrials.gov, PubMed and NIH RePORTER from 2014 to March 2019. We performed a systematic review of studies that assess tenofovir disoproxil fumarate (TDF)‐based oral PrEP safety in pregnant and breastfeeding HIV‐uninfected women.Results and discussion: We identified 14 completed (n = 5) and ongoing/planned (n = 9) studies that evaluate maternal and/or infant outcomes following PrEP exposure during pregnancy or breastfeeding. None of the completed studies found differences in pregnancy or perinatal outcomes associated with PrEP exposure. Nine ongoing studies, to be completed by 2022, will provide data on >6200 additional PrEP‐exposed pregnancies and assess perinatal, infant growth and bone health outcomes, expanding by sixfold the data on PrEP safety in pregnancy. Research gaps include limited data on (1) accurately measured PrEP exposure within maternal and infant populations including drug levels needed for maternal protection; (2) uncommon perinatal outcomes (e.g. congenital anomalies); (3) infant outcomes such as bone growth beyond one year following PrEP exposure; (4) outcomes in HIV‐uninfected women who use PrEP during pregnancy and/or lactation.Conclusions: Expanding delivery of PrEP is an essential strategy to reduce HIV incidence in pregnancy and breastfeeding women. Early safety studies of PrEP among pregnant women without HIV infection are reassuring and ongoing/planned studies will contribute extensive new data to bolster the safety profile of PrEP use in pregnancy. However, addressing research gaps is essential to expanding PrEP delivery for women in the context of pregnancy.